Pulmonx (LUNG)
Builds bronchoscopic emphysema treatments around Zephyr valves and patient-selection tools.
$2.01
vs last close−0.05 (−2.48%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 61.03% | 26.21M shares | |
|---|---|---|---|
| 112 holders · as of Jun 30, 2026 | |||
| Insiders | 19.32% | 8.30M shares | |
| 15 holders · as of Sep 3, 2026 | |||
| Strategic holders | 3.46% | 1.49M shares | |
| 1 holder · as of Jul 14, 2021 | |||
| Other | 16.19% | 6.95M shares | |
| remainder | |||
42.95M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
112 holders · 26.21M shares · 20 new positions · 57 increased · 34 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Primecap Management Co/CA/ | 4.61M | 10.74% | −112.7K | Aug 14, 2026 |
| Morgan Stanley | 2.92M | 6.81% | −1.07M | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 2.79M | 6.49% | 0 | Aug 11, 2026 |
| Vanguard Capital Management LLC | 1.63M | 3.80% | −4.0K | Aug 13, 2026 |
| Exoduspoint Capital Management, LP | 1.22M | 2.85% | −720.3K | Aug 14, 2026 |
| Almitas Capital LLC | 1.06M | 2.48% | +1.06Mnew | Aug 17, 2026 |
| BlackRock, Inc. | 882.5K | 2.05% | −1.78M | Aug 7, 2026 |
| Stonepine Capital Management, LLC | 815.4K | 1.90% | +47.1K | Aug 17, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Primecap Management Co/CA/ | 12.16% | 4.96M | 13G | Nov 13, 2025 |
| Morgan Stanley | 8.50% | 3.39M | 13G | May 7, 2025 |
| BlackRock, Inc. | 6.80% | 2.69M | 13G | Apr 24, 2025 |
| Soleus Capital Master Fund, L.P. | 6.50% | 2.67M | 13G | Mar 9, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 1, 2026 | David Aaron Lehmanofficer: General Counsel | Sale · 4 lots | 14,334 | $2.26 | 361,827 |
| Sep 1, 2026 | Srikanth Radhakrishnanofficer: Chief Science & Techn. Officer | Sale · 4 lots | 14,245 | $2.26 | 316,994 |
| Sep 1, 2026 | Glendon E. III Frenchdirector, officer: President and CEO | Sale · 2 lots | 41,882 | $2.26 | 1,137,936 |
| Sep 1, 2026 | Geoffrey Beran Roseofficer: Chief Commercial Officer | Sale · 4 lots | 7,879 | $2.26 | 449,832 |
| Mar 2, 2026 | David Aaron Lehmanofficer: GENERAL COUNSEL | Sale · 4 lots | 12,237 | $1.43 | 240,755 |
| Mar 2, 2026 | Geoffrey Beran Roseofficer: CHIEF COMMERCIAL OFFICER | Sale · 4 lots | 7,732 | $1.43 | 365,734 |
| Mar 2, 2026 | Glendon E. III Frenchdirector, officer: President and CEO | Sale · 3 lots | 67,813 | $1.43 | 1,409,511 |
| Mar 2, 2026 | Srikanth Radhakrishnanofficer: Chief Science &Techn. Officer | Sale · 4 lots | 10,483 | $1.43 | 170,736 |
| Dec 8, 2025 | Daniel P. Florindirector | Sale | 23,321 | $1.99 | 93,910 |
| Dec 1, 2025 | David Aaron Lehmanofficer: GENERAL COUNSEL | Sale · 4 lots | 10,278 | $1.57 | 252,992 |
House and Senate disclosures
Not reported.